lyme3m
11-11-2008, 06:55 PM
I'm curious to know what you all think about Cell Therapeutics, Inc. (CTIC)? They have been hammered by dilution and the MM's serverly over the last year and the stock is now trading at $0.35. They released PR today on the phase III trials stating they have meet their goals for Pixantrone. As well, they released PR on positive data for Zevalin(R) + Rituximab. ( http://www.tradingmarkets.com/.site/news/Stock%20News/2009745/ )
CTIC is scheduled for meetings with the FDA in Decemeber regarding Zevalin sBLA acceptance, a decision re: priority review for Zevalin, and the Pixatrone pre-NDA FDA meeting.
Even though the stock has been hammered, and investors have lost faith in management, I feel this stock is going to fly or the company will be bought out by Novartis. Even with the debt CTIC has incurred, the company is trading at way below it's real book value, especially when you look at the estimated 34~40 million in sales from Zevalin in 2009 alone.
http://www.marketwatch.com/news/story/ZevalinR-Following-Short-Course-Chemotherapy/story.aspx?guid=%7B36C9D4D8-3238-4FDF-968C-B27A6D983166%7D
http://www.reuters.com/article/governmentFilingsNews/idUSBNG42057820081111
Check out the webcast from today, 11/11/2008 here - http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-calendar
I'd love to get some feedback.
Charlie
CTIC is scheduled for meetings with the FDA in Decemeber regarding Zevalin sBLA acceptance, a decision re: priority review for Zevalin, and the Pixatrone pre-NDA FDA meeting.
Even though the stock has been hammered, and investors have lost faith in management, I feel this stock is going to fly or the company will be bought out by Novartis. Even with the debt CTIC has incurred, the company is trading at way below it's real book value, especially when you look at the estimated 34~40 million in sales from Zevalin in 2009 alone.
http://www.marketwatch.com/news/story/ZevalinR-Following-Short-Course-Chemotherapy/story.aspx?guid=%7B36C9D4D8-3238-4FDF-968C-B27A6D983166%7D
http://www.reuters.com/article/governmentFilingsNews/idUSBNG42057820081111
Check out the webcast from today, 11/11/2008 here - http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-calendar
I'd love to get some feedback.
Charlie